The effect of drugs in altering susceptibility to motion sickness in aerobatics and the slow rotation room by Deane, F. R. et al.
THE EFFECT OF DRUGS IN ALTERING SUSCEPTIBILITY 
I 
TO MOTION SICKNESS IN AEROBATICS AND THE 
SLOW ROTATION ROOM 
I Frederick R .  Deane, Charles D. Wood, Ashton Graybiel, and Arthur C. Cawrse 
JOINT REPORT I 
I 
N67- 2 6 2  7.0. _. 
NAVAL AEROSPACE MEDICAL INSTITUTE 
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION 
June 1966 
Distribution of this document is  unlimited. 
https://ntrs.nasa.gov/search.jsp?R=19670016941 2020-03-12T11:26:11+00:00Z
Distribution of this document i s  unlimited. 
THE EFFECT OF DRUGS IN ALTERING SUSCEPTIBILITY 
I .  
~ 
TO MOTION SICKNESS IN AEROBATICS AND THE 
, SLOW ROTATION ROOM* 
Frederick R. Deane, Charles D. Wood, Ashton Graybiel, and Arthur C. Cawrse 
Bureau of Medicine and Surgery 
MR005.13-6001.1.132 
NASA Order R-93 
Released by 
Captain H. C. Hunley, MC, USN 
Commanding Officer 
*This research was conducted under the sponsorship of the Office of Advanced Research 
and Technology, National Aeronautics and Space Administration. 
3 June 1966 
NAVAL AEROSPACE MEDICAL INSTITUTE 
NAVAL AEROSPACE MEDICAL CENTER 
PENSACOLA , FLORl DA 
SUMMARY PAGE 
THE PROBLEM 
To compare susceptibility to motion sickness and the efficacy of exemplary 
drugs in the prevention of motion sickness i n  the SRR and airsickness in  aerobatics. 
FINDINGS 
Individual difference in  drug effectiveness was demonstrated to be significant 
at the .01 level or better and was similar under the two conditions. Susceptibility to 
motion sickness in  the SRR was generally a good predictor of susceptibility i n  aero- 
batics in eight subiects, but in the remaining two i t  was grossly i n  error. A combina- 
tion of scopolamine and d-amphetamine was by far the most effective of the drugs 
tested under both conditions. 
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INTRODUCTION 
susceptibility to canal sickness, a type of  motion sickness experienced in  a rotating 
environment. The relative value of  exemplary drugs of different categories i n  reducing 
The basic purpose of  the present experiment was to extend these studies by 
were transferable to another force environment. This was done by comparing in the 
same group of  subjects their susceptibility to motion sickness and the efficacy of exem- 
plary drugs in  the prevention of canal sickness in the SRR and airsickness in aerobatics. 
I demonstrating whether and to what extent the findings in  the Slow Rotation Room (SRR) 
I PROCEDURE 
Eighteen healthy Navy enlisted men, 18-21 years of age, assigned to the 
Naval Aerospace Medical Institute, were screened in a single (nonmedicated) trial 
o f  the aerobatics described below. To allow for possible habituation with continued 
exposure and to permit maximum separation of  end points under the expected drug 
benefit, the ten most airsickness susceptible were chosen as study subjects. 
Seven exemplary drugs were pulverized and each was placed in identical 
gelatin capsules, as were three individual glucose placebos (Table I). 
Each "drug" was presented once to each subject in  each environment according 
to a double blind, order-confounding, Latin Square schedule (Table 11) .  This design 
was developed by R. J . Wherry, Jr., (9) for use where learning, adaptation, or residu- 
al treatment effects may be suspected to be present. Usabie i n  squares of 4, 6, 10, 12, 
16, 18, et cetera units per side, the design provides for a given drug to be both pre- 
ceded and followed only once by any other drug in  the total number of trials. The 
coding of drugs was changed between the air and SRR trials to avoid repetition of  the 
presentation order. 
The rotating force environment was generated i n  the Pensacola Slow Rotation 
I 
Room, an essentially circular, windowless room, 15 feet in  diameter and centered about 
the rotational axis of a human centrifuge (4). The Dial Test (6) provided a standardized 
series of  tape-recorder paced head movements in  sequences of five motions at six-second 
intervals. The strength of  the canal sickness producing stimulus of gyroscopic forces on 
the vestibular system with head motion outside the plane of room rotation varies with the 
speed of rotation. Th is  allows ''customizing" the stimulus to subject susceptibility level. 
I 
I ~ 
Subject calibration at 7.5, 10, 15, and 20 rpm prior to the SRR portion of the 
study determined an optimal rotation speed for a given subject so that canal sickness 
could be expected for the nonmedicated subject in  from five to fifteen sequences. When 
1 
Table I 
Drugs and Dosages Used in Aerobatics and SRR Dial Test Studies 
Dosage 
Drug (mg) 
Scopo lamine with 
d-Amphetamine (Dexedrine) 
D-Amphetamine (Dexedrine) 
Cinnarazine (Mi trona I ) 
Cyclizine (Marazine) 
Meclizine (Bonamine) 
Phenoxybenzamine (Dibenzy lene) 
Prochlorperuzine (Compazine) 
Placebos 1, 2, and 3 (glucose) 
0.6 
10.0 
10.0 
50.0 
50.0 
50.0 
20.0 
10.0 
Table II 
Latin Square Used To Schedule the Order of Drug Presentation in the Air or 
on the SRR * 
Trial 
Subject 1 2 3  4 5 6 7  8 9 10 
Hi  
Le 
We 
Br 
Du 
Po 
01 
Se 
Mi 
H O  
1 2 
2 4 
3 6 
4 8 
5 10 
6 1 
7 3 
8 5 
9 7 
10 9 
3 4 5 6 
6 8 10 1 
9 1 4 7 
1 5 9 2 
4 9 3 8 
7 2 8 3 
10 6 2 9 
2 10 7 4 
5 3 1 10 
8 7 6 5 
7 
3 
10 
6 
2 
9 
5 
1 
8 
4 
8 9 
5 7 
2 5 
10 3 
7 1 
4 10 
1 8 
9 6 
6 4 
3 2 
10. 
9 
8 
7 
6 
5 
4 
3 
2 
1 
"Numbers inside the square represent drugs. 
3 
i t  was found that no single speed could be used for al l  ten subjects, 10 and 20 rpm, 
respectively, were selected as test speeds for each of two groups of  five subjects. 
I 
The clr env~rcnrnent c~n;i;ted of an observer-monitored subject seated facing 
aft in  the rear compartment of a single-engine AlE "Skyraider" aircraft during a maxi- 
I 
. I  
I 
mum of twenty-four aerobatic maneuvers. After a level climb to 1 1,000 feet in the 
working area under VFR conditions, the same pilot throughout performed the following 
sequence of maneuvers: 1-4) 3.5 G 3600 steep turns alternately left and right during 
which the subject made 450 head tilts forward, back, and to the sides at two-second 
intervals; 5) nine wing-rocking and porpoising motions with the subject's gaze focused 
inside the aircraft; 6 and 7) wing-overs left and right; 8 and 9) aileron r o l l s  left and 
right; 10 and 11) barrel rolls left and right; 12) a split-S with 4 G pullout. During 
the final six maneuvers, the subject's attention was focused on reading material held 
i n  his lap. Maneuvers 1-4 required about 6,000 feet, 5-1 1 were at a nearly constant 
altitude, and 12 required 3,000 feet. The entire sequence lasted fifteen minutes and 
was repeated once after return to 1 1 , 000 feet i f  an end point had not been reached. 
The same stimulus strength in  the air was experienced by al l  ten subjects. 
The end point for diagnosis o f  motion sickness, based on the criteria shown in 
Table 1 1 1  was Malaise 111 (11). When this stage was reached, straight and level flight 
was immediately resumed or, in  the SRR, the head was fixed and rotation stopped. A 
maximum of twenty-four maneuvers in  the air or sixty sequences (300 head movements) 
on the SRR was allowed i f  Malaise 111 was not reached. Subjects were instructed to 
report the same level of discomfort and a similar end point in  each trial. Scoring was 
in terms of the number of maneuvers (twenty-four maximum) or sequences (sixty maxi- 
mum) completed in reaching Malaise 1 1 1 .  
Data were analyzed in  two ways. A rank order of  drug effectiveness (the 
average o f  the scores of ten subjects for a given drug) and of subject susceptibility 
(the average of the three placebo scores for a given subject) was obtained for each 
environment. During the SRR nonmedicated calibration runs, each of  the five men 
later run at 20 rpm in the drug trials was considerably less susceptible than al l  five 
men later run at 10 rpm. In assigning a rank order of subject susceptibility, i t  was 
assumed that this was also true i n  the placebo trials. A rank-difference coefficient 
of  correlation for subject susceptibility and drug effectiveness i n  the two environments 
was obtained for significance testing. 
In addition, since the aerobatic maneuvers were assumed to be comparable, 
the data were computer analyzed for each environment separately by the analysis of 
variance. A graphical comparison of drug effectiveness was made, expressing it as 
the percentage increase in  number of maneuvers or sequences for a given drug over 
that with Placebo 1. 
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RESULTS 
Rank order of subject susceptibility In e ~ c ! i  environment i s  shown in  Table IV. 
Whiie those subjects more susceptible to sickness in the air were generally so on the 
SRR, exceptions occurred, e .g . , subjects Le and Po. The rank-difference coefficient 
of  correlation was not significant at the .05 level. 
Rank order of drug effectiveness in  each environment i s  shown in  Table V. 
The rank-difference coefficient of correlation for the two conditions was significant 
at the .05 level. 
In the analysis of  variance, drug effect was significant at the .01 and .001 
levels in the air and SRR, respectively. Subject susceptibility i n  the air was signifi- 
cant at the .001 level. However, while a given subject was rotated at a constant 
speed for the drug trials, allowing a rank order of susceptibility to be assigned based 
on the calibration run data, subject susceptibility on the SRR was not meaningful 
since different subjects were rotated at two different speeds for the drug trials. 
Trial order was not significant in  either condition; habituation was not shown 
under these exposure conditions. 
Graphical comparison of  drug effectiveness in the air and in the SRR i s  shown 
in  Figure 1. Those drugs most effective in  the air were generally most effective on 
the SRR. The three separately treated placebos were very closely grouped (as to 
effectiveness) i n  both environments, indicating their validity for control purposes. 
The scopolamine/d-amphetamine mixture was by far the most effective in both 
conditions. Compared to Placebo 1, the mixture increased tolerance in  the air by 
78 per cent and in the SRR by 188 per cent. No drug was more effective than scopol- 
amine with d-amphetamine in  seven subjects in  the air and i n  eight in  the SRR. 
D-amphetamine alone was the second most effective drug in  both environments, 
being the most effective (alone or one of two) for three of  the ten subjects i n  the air 
and one on the SRR. In the air, cyclizine, cinnarazine, and meclizine provided the 
best protection for one subject each; on the SRR, cinnarazine was the most effective 
i n  two subjects. Dibenzylene had an unfavorable effect i n  both environments while 
meclizine apparently led to an increase in susceptibility in  the SRR. 
Side effects were minor and randomly dispersed with respect to drugs and 
subjects; scopolamine plus d-amphetamine did not produce symptoms significantly 
different or greater than placebos. 
DISCUSSION 
In the present study i t  was not possible to equate completely one aerobatic 
maneuver with al l  others, although they were roughly similar in  stress duration, type, 
6 
Table IV 
Rank Order of Subject Susceptibility in the Air and SRR" 
Subject 
Ho Le Mi Br 01 Se Po We Du H i  
I 
I A i r  1.5 1.5 3.0 4.0 5.5 5.5 7.5 7.5 9.0 10.0 
, S RR 2.0 9.0 3.0 6.0 5.0 4.0 1.0 7.0 8.0 10.0 
* 1 = Most sensitive; 10 = least sensitive 
Table V 
Rank Order of Drug Effectiveness in the Air and SRR* 
Drug Air SRR 
Scopolamine and d-Amphetamine 
d -Amphetamine 
Proc h lor pe raz i ne (Co m pazi ne) 
Cycl izine (Marazine) 
Placebo 2 
Mecl izine (Bonamine) 
Placebo 3 
Ci nnarazine (Mi trona1 ) 
Placebo 1 
Phenoxybenzamine (Dibenzylene) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
1 
2 
7 
4 
5 
10 
6 
3 
8 
9 
~~ ~ 
* 1 = Most effective; 10 = least effective 
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and strength. Hence, in  the strictest sense, only a rank order comparison of drug 
coefficients of correlation at the .05 level, the SRR Dial Test provided valid informa- 
tion regarding the effectiveness of exemplary drugs under the air conditions of the 
I *  effectiveness and of subject susceptibility was possible. Considering rank-difference 
l 
I 
I .  experiment . 
Additional data are provided by assuming that one aerobatic maneuver was 
essentially equivalent to every other, thereby making the number of  maneuvers a 
linear function of stress provided. With this assumption, drug effectiveness i n  the 
air and SRR was significant at the .01 and .001 levels, respectively, and may be 
compared as in Figure 1. The essentially linear placement of points supports the 
application of the SRR drug data to aerobatic conditions as does the close grouping 
of the three placebos treated individually. 
The SRR Dial Test with the Malaise 111 end point has many advantages. It 
provides a standardized, reproducible stimulus which may be widely varied in  strength, 
ended immediately by head fixation and cessation of rotation, and repeated with a 
minimum of adaptation or the reduction of subject motivation due to emesis, allowing 
a subject to serve as his own control. It appears that this laboratory test procedure 
i s  more useful than some other devices, e.g., swings, which have been somewhat 
doubtful indicators of drug effectiveness under field conditions (2). Extension of 
this test procedure to other drugs with extrapolation to air conditions seems warranted, 
allowing great savings in  experimental outlay while providing field applicable infor- 
mation. 
While this study confirms that susceptibility to SRR canal sickness generally 
predicts sensitivity to airsickness under aerobatic conditions (7), a correlation which 
i s  not significant at the .05 level was found. Other studies (2) have shown that sus- 
ceptibi l i ty in  one motion sickness producing environment i s  not an infallible predictor 
for another. One might speculate that variability in  flight experience and anxiety 
levels, as well as the differences i n  the stimuli provided in  the two environments, 
may be contributory. 
Within the exemplary drugs studied, scopolamine, a parasympatholytic, 
combined with d-amphetamine, a sympathomimetic, was the most effective medica- 
tion by a wide margin; d-amphetamine alone was second in  both environments, con- 
firming studies in  this laboratory (10, l l )  and others (1,2,5,8,12). Dibenzylene, a 
sympatholytic, was shown to increase motion sickness susceptibility slightly as reported 
by Chinn et a1.(3). These findings harken to earlier theories (5) which noted that 
motion sickness symptoms resemble parasympathetic overactivity, may be reproduced 
by anticholinesterases such as physostigmine, and might be prevented or reduced by 
drugs shifting the balance toward the sympathetic. It i s  difficult to reconcile a single 
centrally active mechanism with these facts since scopolamine has a depressant action 
and both d-amphetamine and Dibenzylene are stimulants. However, Dibenzylene has 
the reported central side effect of producing nausea and emesis in  nonmoving environ- 
ments. 
9 
Compazine, a phenothiazine tranqui Ilizer, was moderately effective in the 
aerobatic portion (third, next to d-amphetamine), probably through reduction of 
anxiety. In the SRR i t  was ineffective as i n  previous studies (10,l I ) .  
The three antihistamines, cyclizine, cinnarazine, and meclizine, provided 
contradictory results. Cyclizine was moderately effective in  both experimental 
environments while the related cinnarazine was effective in the SRR but not in the 
air. Meclizine provided a contrast to previous findings (10-12) in  that it was inef- 
fective in the air and increased susceptibility in the SRR. However, subject Hi, 
usually the most motion sickness resistant subject and high scorer, had an atypical, 
extremely low score and probably during his SRR meclizine trial, a mi ld  gastroenteritis 
was developing. Recalculation of  rank order of drug effects on the SRR, eliminating 
Hi's scores, places meclizine i n  a somewhat effective range (sixth) while changing 
other positions l itt le. Aside from speculation as to the quality of  meclizine stock 
used, no other explanation can be given. 
This study supports the contention that the SRR Dial Test is an effective 
standardized laboratory procedure for the investigation of antimotion sickness drugs 
and that findings, generally, may be extrapolated to air conditions. Further anti- 
motion sickness drug screening, the establishment of  the optimal scopolamine and 
d-amphetamine combination, and comparison of  drug effectiveness at sea and on 
other motion simulators are suggested. 
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